{"status":"OK","data":{"id":2970158,"identifier":"DVN/QUBILA","persistentUrl":"https://doi.org/10.7910/DVN/QUBILA","protocol":"doi","authority":"10.7910","publisher":"Harvard Dataverse","publicationDate":"2017-02-15","storageIdentifier":"s3://dvn-cloud:10.7910/DVN/QUBILA","latestVersion":{"id":97097,"storageIdentifier":"s3://dvn-cloud:10.7910/DVN/QUBILA","versionNumber":1,"versionMinorNumber":0,"versionState":"RELEASED","productionDate":"Production Date","lastUpdateTime":"2017-02-15T10:42:13Z","releaseTime":"2017-02-15T10:42:13Z","createTime":"2017-01-12T02:20:19Z","license":"CC0","termsOfUse":"CC0 Waiver","metadataBlocks":{"citation":{"displayName":"Citation Metadata","fields":[{"typeName":"title","multiple":false,"typeClass":"primitive","value":"CRISPR Therapeutics CRISPR Patent Licenses and Press Releases"},{"typeName":"author","multiple":true,"typeClass":"compound","value":[{"authorName":{"typeName":"authorName","multiple":false,"typeClass":"primitive","value":"Sherkow, Jacob"},"authorAffiliation":{"typeName":"authorAffiliation","multiple":false,"typeClass":"primitive","value":"New York Law School"}}]},{"typeName":"datasetContact","multiple":true,"typeClass":"compound","value":[{"datasetContactName":{"typeName":"datasetContactName","multiple":false,"typeClass":"primitive","value":"Sherkow, Jacob"},"datasetContactAffiliation":{"typeName":"datasetContactAffiliation","multiple":false,"typeClass":"primitive","value":"New York Law School"},"datasetContactEmail":{"typeName":"datasetContactEmail","multiple":false,"typeClass":"primitive","value":"jacob.sherkow@nyls.edu"}}]},{"typeName":"dsDescription","multiple":true,"typeClass":"compound","value":[{"dsDescriptionValue":{"typeName":"dsDescriptionValue","multiple":false,"typeClass":"primitive","value":"This dataset contains PDFs of CRISPR patent licenses, and press releases containing patent license information, originating from CRISPR Therapeutics, Cambridge, MA."}}]},{"typeName":"subject","multiple":true,"typeClass":"controlledVocabulary","value":["Law","Medicine, Health and Life Sciences"]},{"typeName":"depositor","multiple":false,"typeClass":"primitive","value":"Sherkow, Jacob"},{"typeName":"dateOfDeposit","multiple":false,"typeClass":"primitive","value":"2017-01-11"}]}},"files":[{"label":"CRISPR Therapeutics and Bayer JV License, SEC .pdf","restricted":false,"version":1,"datasetVersionId":97097,"dataFile":{"id":2970160,"persistentId":"doi:10.7910/DVN/QUBILA/3CXCVG","pidURL":"https://doi.org/10.7910/DVN/QUBILA/3CXCVG","filename":"CRISPR Therapeutics and Bayer JV License, SEC .pdf","contentType":"application/pdf","filesize":951389,"storageIdentifier":"s3://dvn-cloud:159907965ef-7e5688fe54c8","rootDataFileId":-1,"md5":"1ae4487f5076874c199c3737b63f6521","checksum":{"type":"MD5","value":"1ae4487f5076874c199c3737b63f6521"}}},{"label":"CRISPR Therapeutics to Casebia License, SEC.pdf","restricted":false,"version":1,"datasetVersionId":97097,"dataFile":{"id":2970161,"persistentId":"doi:10.7910/DVN/QUBILA/QY7FPG","pidURL":"https://doi.org/10.7910/DVN/QUBILA/QY7FPG","filename":"CRISPR Therapeutics to Casebia License, SEC.pdf","contentType":"application/pdf","filesize":295415,"storageIdentifier":"s3://dvn-cloud:15990796a2f-7aacf5d40f0d","rootDataFileId":-1,"md5":"e33fbc2a287de84fdf30d42ece25e614","checksum":{"type":"MD5","value":"e33fbc2a287de84fdf30d42ece25e614"}}},{"label":"CRISPR Therapeutics to Vertex License, SEC.pdf","restricted":false,"version":1,"datasetVersionId":97097,"dataFile":{"id":2970159,"persistentId":"doi:10.7910/DVN/QUBILA/ZYQSXE","pidURL":"https://doi.org/10.7910/DVN/QUBILA/ZYQSXE","filename":"CRISPR Therapeutics to Vertex License, SEC.pdf","contentType":"application/pdf","filesize":687540,"storageIdentifier":"s3://dvn-cloud:1599079713e-68eac67d6d9a","rootDataFileId":-1,"md5":"4f529fd37d0d9bb0917034bd012d05f4","checksum":{"type":"MD5","value":"4f529fd37d0d9bb0917034bd012d05f4"}}}]}}}